Data Insights

AT-101 by A28 Therapeutics for Hepatocellular Carcinoma: Likelihood of Approval

AT-101 is under clinical development by A28 Therapeutics and currently in Phase I for Hepatocellular Carcinoma. According to GlobalData, Phase...

Data Insights

AT-101 by Abclon for Diffuse Large B-Cell Lymphoma: Likelihood of Approval

AT-101 is under clinical development by Abclon and currently in Phase II for Diffuse Large B-Cell Lymphoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - AT-101 in Diffuse Large B-Cell Lymphoma

Data Insights

AT-101 by Abclon for Mantle Cell Lymphoma: Likelihood of Approval

AT-101 is under clinical development by Abclon and currently in Phase II for Mantle Cell Lymphoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - AT-101 in Mantle Cell Lymphoma

Data Insights

AT-101 by Abclon for Follicular Lymphoma: Likelihood of Approval

AT-101 is under clinical development by Abclon and currently in Phase II for Follicular Lymphoma. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - AT-101 in Follicular Lymphoma

Data Insights

AT-101 by Abclon for Marginal Zone B-cell Lymphoma: Likelihood of Approval

AT-101 is under clinical development by Abclon and currently in Phase II for Marginal Zone B-cell Lymphoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - AT-101 in Marginal Zone B-cell Lymphoma

Data Insights

AT-101 by Abclon for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval

AT-101 is under clinical development by Abclon and currently in Phase II for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic...